New antibody combo aims to tame rare blood disease
NCT ID NCT04754945
First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This early-phase trial tests whether adding the drug isatuximab to standard chemotherapy can safely treat people with high-risk AL amyloidosis, a rare disease where abnormal proteins damage organs. Eleven participants will receive the combination to see if it reduces toxicity and improves disease control. The goal is to find a better upfront therapy for this aggressive form of the condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Isatuximab (a monoclonal antibody) combined with bortezomib and cyclophosphamide
- What this could lead to
- If it works, this could offer a safer, more effective upfront treatment for high-risk AL amyloidosis, potentially improving disease control and survival.
- What could go wrong
- This is a very early (Phase 1) trial with only 11 participants, so results may not apply broadly. The treatment may still cause serious side effects or fail to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University
New York, New York, 10032, United States
-
Emory University Hospital Midtown
Atlanta, Georgia, 39322, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
UT Southwestern
Dallas, Texas, 75390, United States
-
University of California
Orange, California, 92868, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Targeting antibody stop amyloid buildup in its tracks?
- Can a radioactive peptide spot hidden amyloid in the heart?
- Real-world data on multiple myeloma immunotherapies could reshape monitoring and improve survival
- Nationwide registry aims to crack the code of a rare protein-clogging disease
- New scan spots hidden organ damage before symptoms start
- Could a simple scan unlock better heart treatment?